Low serum total testosterone level as a predictor of upgrading in low-risk prostate cancer patients after radical prostatectomy: A systematic review and meta-analysis

Investig Clin Urol. 2022 Jul;63(4):407-414. doi: 10.4111/icu.20210459. Epub 2022 May 25.

Abstract

Purpose: To investigated the association between serum total testosterone and Gleason score upgrading of low-risk prostate cancer after radical prostatectomy (RP).

Materials and methods: Medline, Web of Science, Embase, and Cochrane Library databases were searched to identify eligible studies published before October 2021. Multivariate adjusted odds ratios (ORs) and associated 95% confidence intervals (CIs) were calculated using random or fixed effects models.

Results: Five studies comprising 1,203 low-risk prostate cancer patients were included. The results showed that low serum total testosterone (<300 ng/dL) is associated with a high rate of Gleason score upgrading after RP (OR, 2.3; 95% CI, 1.38-3.83; p<0.001; I², 92.2%). Notably, sensitivity and meta-regression analyses further strengthen the reliability of our results.

Conclusions: Our results support the idea that low serum total testosterone is associated with a high rate of Gleason score upgrading in prostate cancer patients after RP. It is beneficial for urologist to ensure close monitoring of prostate-specific antigen levels and imaging examination when choosing non-RP treatment for low-risk prostate cancer patients.

Keywords: Meta-analysis; Prostatectomy; Prostatic neoplasms; Testosterone.

Publication types

  • Meta-Analysis
  • Systematic Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Male
  • Neoplasm Grading
  • Prostate
  • Prostate-Specific Antigen
  • Prostatectomy* / methods
  • Prostatic Neoplasms* / surgery
  • Reproducibility of Results
  • Retrospective Studies
  • Testosterone

Substances

  • Testosterone
  • Prostate-Specific Antigen